Gufic Biosciences Limited · NSE:GUFICBIO
Gufic Biosciences — H1 FY24 Earnings Presentation
33 slides from Gufic Biosciences's earnings presentation, Nov 17, 2023
Slide 1: Exchange filing cover letter
298/LG/SE/NOV/2023/GBSL November 17, 2023 To, To, BSE Limited National Stock Exchange of India Limited Phiroze Jeejeebhoy Towers, Exchange Plaza, Bandra Kurla Complex, Dalal Street, Fort, Mumbai – 400 001 Bandra (E), Mumbai – 400 051 Scrip Code: 509079 Scrip Symbol: GUFICBIO Subject: Investor Presen
Slide 2: Delivering Care & Cure - Investor Presentation
Delivering Care & Cure Investor Presentation November 2023
Slide 3: Safe Harbor
Safe Harbor This presentation has been prepared by and is the sole responsibility of Gufic Biosc iences Limited (the “ Company”). By accessing this presentation, you are agreeing to be bound by the trailing restrictions . This presentation does not constitute or form part of any offer or invitation
Slide 4: H1 FY24 Business & Financial Highlights
H1 FY24 Business & Financial Highlights
Slide 5: H1 FY24 Business Highlights
H1 FY24 Business Highlights Gearing up for Indore Facility to go live Domestic Business Breakup • R&D Advancements: Our investment in R&D for molecules at the Indore facility continues to yield promising results, enhancing our product pipeline • Time-to-Market Efficiency: Our efforts are directed to
Slide 6: H1 FY24 Business Highlights
H1 FY24 Business Highlights • Venturing into Total Parenteral Nutrition Market: We are strategically poised to enter the rapidly expanding market of Total Parenteral Nutrition. Our ongoing product development efforts encompass Single Chamber and Multi Chamber bags, a move that aligns with evolving h
Slide 7: H1 FY24 Business Highlights
H1 FY24 Business Highlights Ferticare Division • Increased geographical presence and market penetration : As a division we have established presence in almost 60% of all the IVF centers in India. Moreover, our products Have emerged as the go to products for more than 50% Gynecologists to tackle infe
Slide 8: H1 FY24 Business Highlights
H1 FY24 Business Highlights Healthcare, Stellar & Spark Division • Strategic ENT Specialty Inclusion : The deliberate inclusion of the ENT specialty into our portfolio adds significant strength to our existing antibiotic portfolio. This strategic move enhances our capability to address a broader spe
Slide 9: H1 FY24 Business Highlights
H1 FY24 Business Highlights Aestherderm & Neurocare Division • Strengthening Market Position through Splitface Trial Success: Our successful completion of a splitface trial comparing Stunnox against a product from the market leader has yielded remarkable results. This achievement has not only create
Slide 10: H1 FY24 Business Highlights
H1 FY24 Business Highlights Arisia, The Center of Excellence • Elevating Aesthetic Excellence in Mumbai: Introducing Arisia, our Center of Excellence in Mumbai—a cutting-edge aesthetic clinic and training center that redefines the benchmarks for excellence in aesthetic care. Arisia is meticulously d
Slide 11: Research & Development
Research & Development Update on R&D Update on Selvax • Peptides R&D : • Positive Results from Mouse Studies: • Paving the Way for In -house Critical API • Selvax conducted comprehensive studies in mice using established pancreatic cancer Manufacturing: Our foray into peptides research models and de
Slide 12: Strategic Initiatives
Strategic Initiatives Strategic Initiatives that will further amplify growth over the next few years Increase in overall market and market share in Leverage new biological Botulinum Toxin range of Increase market share in technology platform to products through Commercialization of contract manufact
Slide 13: Profit & Loss Statement
Profit & Loss Statement Pa r t i c u l a rs ( i n R s . C r o re) Q2 FY24 Q2 FY23 H1 FY24 H1 FY23 To ta l Rev e n u e 215.2 175.7 410.8 341.3 E B I T DA 39.7 33.4 76.1 67.0 E B I T DA M a r g i n % 18.4% 19.0% 18.5% 19.6% P ro f i t B efo re Ta x 30.9 27.3 59.0 55.5 P BT M a r g i n s % 14.4% 15.5%
Slide 14: Company Overview
Company Overview
Slide 15: About Gufic Biosciences
About Gufic Biosciences Research based Pharmaceutical Company recognized for its innovative, high quality Pharmaceuticals Nutraceuticals, Natural Herbal products One of the Largest Manufacturers of Lyophilized Injections in India with a wide range of products in various therapy areas BUSINESS STRUCT
Slide 16: World Class Manufacturing Infrastructure
World Class Manufacturing Infrastructure Unit - I at Navsari Unit - II at Navsari Gufic - Belgaum Botulinum Toxin Facility Lyophilized Injectables Facility Natural Products Facility Lyophilized/Powder Injectables Facility Capability to manufacture Liposomal Amphotericin B and Depot Injections Natura
Slide 17: Upcoming World Class Manufacturing Infrastructure
Upcoming World Class Manufacturing Infrastructure Unit - III at Indore Penem Block UPDATE ON CAPEX Indore Lyophilized/Powder Injectables Dedicated facility for Penem Validation Milestone: Validation of the Indore facility is Facility Carbapenems (Lyophilized / Dry on track for completion by Septembe
Slide 18: Botulinum Toxin Facility
Botulinum Toxin Facility Gufic has built a state-of-the-art manufacturing facility for Botulinum Toxin in Navsari Gufic has partnered with Prime Bio, USA for manufacturing Botulinum Toxin API and formulation Gufic is equipped with all the necessary analytical testing procedures for safety and effica
Slide 19: Consolidating the Domestic Branded Business
Consolidating the Domestic Branded Business Products CRITICAL CARE INFERTILITY MASS SPECIALITY 100+ SKU’s Field Force: 250 Field Force: >150 Field Force: >180 200+ Therapy Areas: Antibacterial, Therapy Areas: Hormones, Therapy Areas: Anti Infectives, Antifungal, Pain Management, Recombinant Products
Slide 20: Expanding Creditability in CMO Business
Expanding Creditability in CMO Business Offer CMO services for India and 70+ 150+ Products Reliable CMO service for quality products over a Global Markets Companies across multiple therapy areas decade One of the Largest Supplier of Formulations Liposomal Doxycycline Tigecycline Gonadotropins Micafu
Slide 21: Expanding Geographical Reach
Expanding Geographical Reach 130+ Products registered globally (in 15+ countries) 150+ Products in pipeline for registration (in 30+ countries) CANADA | COSTA RICA | PANAMA | COLUMBIA | CHILE | LATVIA | LITHUANIA | BELARUS | GERMANY | AUSTRIA | PORTUGAL | MOROCCO ALGERIA | DOMINICAN REPUBLIC | VENEZ
Slide 22: Building API Capabilities
Building API Capabilities Special Facility dedicated to API Focused on developing non The categories of API’s infringing, novel, cost manufactured are effective and scalable antifungals, antibacterial, chemical process for APIs, anesthetics and Peptides and Cyclopeptides intermediates for antifungal
Slide 23: Strong Partnership & Licensing Deals
Strong Partnership & Licensing Deals Through our collaborations with global partners that are European leader in IV drug researching to expand the frontiers of pharma and delivery systems. Collaborated biotechnology, Gufic will be a technology bridge to the with Gufic to launch Dual future of health
Slide 24: Extensive Sales, Distribution & IT Infrastructure in India
Extensive Sales, Distribution IT Infrastructure in India 2 Central Warehouses Pan India Presence with a located in North Delhi and field force of 1,000+ West Bhiwandi IT Infrastructure Retail coverage of more than 23 Carrying & Forwarding (C&F) agents across India Integrated IT Systems with Sales 1,
Slide 25: Growth Levers
Growth Levers 1 2 3 INTERNATIONAL INDIA BUSINESS CMO BUSINESS BUSINESS • Consolidation of the Critical Care Infertility • Expand our presence in regulated • Scale up the manufacturing capacity business markets such as US EU • Entry into new therapy areas Dermatology - • Consolidation of the clients
Slide 26: Our Robust R&D and Clinical team to augment growth
Our Robust R&D and Clinical team to augment growth Research & Development (R&D) Clinical Team State-of-the-art R&D Facility in Navsari, Gujarat with expertise in Formulation Development Technology Transfer API Development Patents in various therapy areas Granted: 5 Filed/In-process of filling : 8 Ma
Slide 27: Historical Financials
Historical Financials
Slide 28: Historical Financials
Historical Financials Total Revenue EBITDA & EBITDA Margin Profit After Tax & PAT Margin 15.8% 15.1% 17.8% 19.3% 19.8% 7.4% 5.9% 9.0% 12.3% 11.5% 782 693 151 96 137 491 80 385 360 88 44 57 58 27 23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22* FY23 2019 2020 2021 FY22 FY23 CAGR 18% CAGR 31% CAGR 38
Slide 29: Historical Financials
Historical Financials Particulars (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 FY18 Total Revenue 693.2 782.3 491.4 384.6 359.5 311.6 EBITDA 137.2 151.1 87.7 57.9 56.7 41.6 EBITDA Margin % 19.8% 19.3% 17.8% 15.1% 15.8% 13.4% Profit before Tax 106.7 126.8 57.7 30.1 40.2 30.0 PBT Margin % 15.4% 16.2% 11.7% 7.8
Slide 30: Historical Balance Sheet (Equity & Liabilities)
Historical Balance Sheet (Equity & Liabilities) EQUITY & LIABILITIES (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Equity Share Capital 9.7 9.7 9.7 9.7 9.7 Other Equity 338.1 259.4 163.7 119.6 102.8 Total Equity 347.8 269.1 173.4 129.3 112.5 Non-Current Liabilities Financial Liabilities i. Borrowing
Slide 31: Historical Balance Sheet (Assets)
Historical Balance Sheet (Assets) ASSETS (Rs. Crs.) Mar-23 Mar-22 Mar-21 Mar-20 Mar-19 Non-Current Assets Property, plant and equipment 126.8 105.5 93.8 72.7 70.3 Intangible assets 0.7 0.6 0.4 0.6 0.4 Capital work-in-progress 169.6 40.9 13.4 30.6 9.6 Right of use assets 32.1 9.1 5.8 9.3 0.0 Financia
Slide 32: Historical Cash Flows
Historical Cash Flows Cash Flow Statement (Rs. Crs.) FY23 FY22 FY21 FY20 FY19 Net Profit Before Tax 106.7 126.9 57.7 30.1 35.3 Adjustments for: Non - Cash Items / Other Investment or 29.6 23.2 30.8 24.7 13.4 Financial Items Operating profit before working capital changes 136.4 150.0 88.5 54.8 48.7 C
Slide 33: Thank You
THANK YOU Company: Gufic Biosciences Limited Investor Relations Advisors: Strategic Growth Advisors (SGA) CIN: L24100MH1984PLC033519 CIN: U74140MH2010PTC204285 Mr. Avik Das – Investor Relations Mr. Deven Dhruva / Mr. Harsh Shah avik.das@guficbio.com deven.dhruva@sgapl.net / harsh.shah@sgapl.net Tel: